B&C Biopharm (B&C) is a biopharmaceutical venture company. The company discovers and develops pharmaceutical products for the treatment of the infectious diseases. B&C’s product portfolio includes NS5B inhibitors, BC2125, BC2329, NS3 inhibitors, PPI inhibitors, and antifungal agents. The company conducts research to develop therapeutics for Hepatitis C, NS5B RNA polymerase, and NS3 helicase, among others. Its Korean’s patents for drug discoveries are 446669, 516434, and 516433 among others. The company has strategic alliances with various organizations such as Yuhan Pharm, Equis Pharm, Daewon Pharm, Wayne State University, and Korea University Medical School. It has license and development agreement with XTL Biopharmaceuticals. B&C is headquartered in Yeongtong-gu, Gyeonggi-do, Korea.